HDAC1/6-IN-3

HDAC1/6-IN-3 is a potent HDAC inhibitor. HDAC1/6-IN-3 shows excellent inhibitory activities against HDAC1 (IC50 = 1.1 nM) and HDAC6 (IC50 = 2.7 nM) . HDAC1/6-IN-3 significantly arrests HepG2 cells at the G0/G1 phase and induces apoptosis and pyroptosis. HDAC1/6-IN-3 exhibits significant antitumor activity in the HepG2 xenograft mode. HDAC1/6-IN-3 can be used for the study of cancers such as liver cancer, lung cancer, colon cancer and breast cancer[1].

Product Specifications

CAS Number

[3038691-85-6]

UNSPSC

12352005

Target

Apoptosis; Caspase; HDAC; Pyroptosis; Reactive Oxygen Species (ROS)

Related Pathways

Apoptosis; Cell Cycle/DNA Damage; Epigenetics; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB

Applications

Cancer-programmed cell death

Field of Research

Cancer

Smiles

O=C(NO)CCCCCC(N(C1=CC=C(OC)C=C1)CC2=CSC(C3=CC=CC=C3)=N2)=O

Molecular Formula

C24H27N3O4S

Molecular Weight

453.55

References & Citations

[1]Li Z, et al. Design and synthesis of thiazole-based hydroxamate histone deacetylase inhibitors with potent antitumor efficacy by inducing apoptosis, pyroptosis and cell cycle arrest. Sci Rep. 2025 Jul 9;15 (1) :24589.